Daewoong Pharmaceutical Signs Export Contract for Fexuprazan to China Worth 384.5 Billion KRW

[Asia Economy Reporter Minwoo Lee] Daewoong Pharmaceutical announced on the 18th that it has signed a supply contract worth 384.5 billion KRW for the new drug "Pexuprazan" for the treatment of gastroesophageal reflux disease with Shanghai Haini, a subsidiary of China Yangtze River Pharmaceutical Group. This amount corresponds to 36.43% of the consolidated sales of the previous year.

The company stated, "The contract amount is the sum of the technology fee and the cumulative expected supply amount over 13 years," and explained, "The local development costs in China will be borne by the contracting party, and the minimum purchase quantity is 70% of the contract amount excluding the technology fee."

This content was produced with the assistance of AI translation services.